This technology developed by MindMed and Liechti Lab may help ease some of the concerns surrounding psychedelic therapy.
UK Health Technology Assessment body raises questions over the clinical and cost-effectiveness of Spravato (esketamine).
The scope and validity of this patent will depend on how x-ray diffraction data is interpreted.
A look into the promising potential of artificial intelligence in tackling unmet medical needs in mental healthcare
Nasal spray formulations could offer precision dosing of a spectrum of psychedelic mushroom compounds to consumers.
Market introduction of psychedelics as a therapy looks promising. However, policy and regulatory issues concerning the drug class still exist.
This is the first time psilocybin has been produced from a prokaryotic organism.
Scientific and public opinion is slowly shifting for the potential usage of psilocybin in a variety of conditions. Can the same be said for recreational usage?
FDA approval for psilocybin-assisted therapy for depression appears to be on the horizon.
Pharma companies with expertise in 5-HT3 receptors are focusing on antagonist drugs to combat nausea and vomiting in chemotherapy patients.